Volume 20 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(6): 952-955
YING Xi-hui, LAI Lin-qiang, CHEN Li, YANG Hong-yuan, JI Jian-song, TU Jian-fei. Prognostic analysis of hepatic arterial chemoembolization and radiofrequency ablation combination with different time intervals for patients with advanced hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2022, 20(6): 952-955. doi: 10.16766/j.cnki.issn.1674-4152.002496
Citation: YING Xi-hui, LAI Lin-qiang, CHEN Li, YANG Hong-yuan, JI Jian-song, TU Jian-fei. Prognostic analysis of hepatic arterial chemoembolization and radiofrequency ablation combination with different time intervals for patients with advanced hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2022, 20(6): 952-955. doi: 10.16766/j.cnki.issn.1674-4152.002496
shu

Prognostic analysis of hepatic arterial chemoembolization and radiofrequency ablation combination with different time intervals for patients with advanced hepatocellular carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.002496

  • Key Laboratory of Imaging Diagnosis and Minimally Invasive and Intervention Research of Zhejiang Province, Department of Radiology Lishui Hospital of Zhejiang University, Lishui, Zhejiang 323000, China

Funds:

 WKJ-ZJ-1932

 LGF18H220001

 2018KY933

 2020ZH087

  • Received Date: 2021-07-02
    Available Online: 2022-09-21
    Abstract
  •   Objective  To investigate the appropriate interval between transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in treatment of advanced hepatocellular carcinoma (HCC).  Methods  The clinical data of 99 patients with HCC in Department of Radiology Lishui Hospital of Zhejiang University was retrospectively collected from February 2012 to December 2017. All patients received sequential treatment of TACE and RFA. The treatment interval of TACE and RFA was calculated, and the patients were divided into 3 subgroups: group A (0-5 days, n=30), group B (6-22 days, n=54), and Group C (>22 days, n=15). Recursive segmentation was used to select the most appropriate TACE-RFA interval threshold. The primary study endpoint was overall survival (OS), and the secondary study endpoint was tumor progression-free survival (PFS) and treatment-related adverse events.  Results  The last follow-up time was December 30, 2020. The data showed that longer TACE-RFA time intervals were associated with poor OS (group A vs. group B, P=0.694; group A vs. Group C, P=0.037; group B vs. group C, P=0.023). Among the 15 patients in group C, 73.3% (11/15) died. The median OS of the 3 subgroups were 32.3, 34.1, and 23.2 months, respectively.  Conclusion  The time interval between TACE and RFA is related to the prognosis of HCC patients. The shorter time intervals can improve OS and PFS in HCC patients. However, the optimal time interval still needs to be confirmed by large-scale multi-center clinical trials.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    YUN X, MENG H, ZHOU A F, et al. Efficacy of transcatheter arterial chemoembolization combined with capecitabine and cetuximab in the treatment of colorectal cancer with liver metastasis[J]. J BUON, 2021, 26(3): 1002-1008.
    [2]
    HIROOKA M, HIRAOKA A, OCHI H, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation: Outcomes in Patients with barcelona clinic liver cancer stage B hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2018, 210(4): 891-898. doi: 10.2214/AJR.17.18177
    [3]
    LIU L, LIANG X X, XU X X, et al. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer[J]. Acta Biomater, 2021, 130: 374-384. doi: 10.1016/j.actbio.2021.05.031
    [4]
    SUN M, SHANG P Y, BAI J T, et al. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer[J]. J Clin Lab Anal, 2021, 35(2): e23633. DOI: 10.1002/jcla.23633
    [5]
    HAN T, YANG X D, ZHANG Y, et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis[J]. Biosci Trends, 2019, 13(5): 374-381. doi: 10.5582/bst.2019.01153
    [6]
    《原发性肝癌诊疗规范(年版)》编写专家委员会. 原发性肝癌诊疗规范(2019年版)[J]. 中国临床医学, 2020, 27(1): 140-156. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm

    Expert Committee for the compilation of the standard for diagnosis and treatment of primary liver cancer (EDITION) Standard for diagnosis and treatment of primary liver cancer (2019 Edition)[J]. Chinese Journal of Clinical Medicine, 2020, 27(1): 140-156. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm
    [7]
    CHOE W H, KIM Y J, PARK H S, et al. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(35): 12588-12594. doi: 10.3748/wjg.v20.i35.12588
    [8]
    SOHN W, CHOI M S, CHO J Y, et al. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: Long-term outcomes and predictive factors[J]. Gut Liver, 2014, 8(5): 543-551. doi: 10.5009/gnl13356
    [9]
    ZHAO M, WANG J P, PAN C C, et al. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement[J]. Eur J Radiol, 2012, 81(10): 2717-2725. doi: 10.1016/j.ejrad.2011.10.023
    [10]
    朱德东, 石小军, 王哲, 等. 射频消融联合肝动脉化疗栓塞对大肝癌患者机体抗肿瘤免疫状态的影响[J]. 中华全科医学, 2018, 16(1): 38-40. doi: 10.16766/j.cnki.issn.1674-4152.000010

    ZHU D D, SHI X J, WANG J, et al. Effect of radiofrequency ablation combined transcatheter arterial chemoembolization on antitumor immune status of patients with hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2018, 16(1): 38-40. doi: 10.16766/j.cnki.issn.1674-4152.000010
    [11]
    应希慧, 张登科, 陈丽, 等. 放射性粒子植入在原发性肝癌射频消融后应用人群的初步探讨[J]. 中华医学杂志, 2020, 100(17): 1310-1314. doi: 10.3760/cma.j.cn112137-20200225-00447

    YING X H, ZHANG D K, CHEN L, et al. Differential population screening and efficacy analysis of 125I implantation after radiofrequency ablation of primary liver cancer[J]. National Medical Journal of China, 2020, 100(17): 1310-1314. doi: 10.3760/cma.j.cn112137-20200225-00447
    [12]
    杨晓珍, 张晓勇, 刘海春, 等. 肝动脉化疗栓塞联合射频消融治疗肝癌疗效及预后分析[J]. 中国基层医药, 2016, 23(17): 2609-2612. doi: 10.3760/cma.j.issn.1008-6706.2016.17.013

    YANG X Z, ZHANG X Y, LIU H C, et al. The curative effect and prognostic analysis of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of liver cancer[J]. Chinese Journal of Primary Medicine and Pharmacy, 2016, 23(17): 2609-2612. doi: 10.3760/cma.j.issn.1008-6706.2016.17.013
    [13]
    YIN X, ZHANG L, WANG Y H, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 849. doi: 10.1186/1471-2407-14-849
    [14]
    TANAKA M, ANDO E, SIMOSE S, et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma[J]. Hepatol Res, 2014, 44(2): 194-200. doi: 10.1111/hepr.12100
    [15]
    JIN J, ZHOU T Y, LOU J Y, et al. Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer[J]. J BUON, 2020, 25(6): 2584-2591.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (258) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return